ANI Pharmaceuticals/$ANIP
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About ANI Pharmaceuticals
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Ticker
$ANIP
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
897
ISIN
US00182C1036
Website
ANIP Metrics
BasicAdvanced
$1.2B
-
-$1.15
0.56
-
Price and volume
Market cap
$1.2B
Beta
0.56
52-week high
$77.00
52-week low
$52.50
Average daily volume
438K
Financial strength
Current ratio
2.657
Quick ratio
1.861
Long term debt to equity
139.502
Total debt to equity
142.026
Interest coverage (TTM)
0.45%
Management effectiveness
Return on assets (TTM)
0.82%
Return on equity (TTM)
-4.57%
Valuation
Price to revenue (TTM)
1.727
Price to book
2.86
Price to tangible book (TTM)
-6.64
Price to free cash flow (TTM)
24.829
Growth
Revenue change (TTM)
30.26%
Earnings per share change (TTM)
-171.33%
3-year revenue growth (CAGR)
43.93%
3-year earnings per share growth (CAGR)
-37.19%
What the Analysts think about ANIP
Analyst ratings (Buy, Hold, Sell) for ANI Pharmaceuticals stock.
ANIP Financial Performance
Revenues and expenses
ANIP Earnings Performance
Company profitability
ANIP News
AllArticlesVideos
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·1 week ago
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
GlobeNewsWire·2 weeks ago
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ANI Pharmaceuticals stock?
ANI Pharmaceuticals (ANIP) has a market cap of $1.2B as of June 06, 2025.
What is the P/E ratio for ANI Pharmaceuticals stock?
The price to earnings (P/E) ratio for ANI Pharmaceuticals (ANIP) stock is 0 as of June 06, 2025.
Does ANI Pharmaceuticals stock pay dividends?
No, ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next ANI Pharmaceuticals dividend payment date?
ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders.
What is the beta indicator for ANI Pharmaceuticals?
ANI Pharmaceuticals (ANIP) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.